{"nctId":"NCT01327846","briefTitle":"Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)","startDateStruct":{"date":"2011-04-11","type":"ACTUAL"},"conditions":["Atherosclerosis"],"count":10066,"armGroups":[{"label":"Canakinumab Dose 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab","Drug: Standard of care"]},{"label":"Canakinumab Dose 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab","Drug: Standard of care"]},{"label":"Canakinumab Dose 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab","Drug: Standard of care"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Standard of care"]}],"interventions":[{"name":"Canakinumab","otherNames":["ACZ885"]},{"name":"Placebo","otherNames":[]},{"name":"Standard of care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Study Inclusion Criteria:\n\n* Written informed consent\n* Male, or Female of non-child-bearing potential\n* Age ≥ 18 years.\n* Spontaneous MI at least 30 days before randomization. hsCRP ≥ 2 mg/L\n\nSubstudy 1 Inclusion:\n\n* All Inclusion from Main Study\n* Acquisition of evaluable baseline MRI images of bilateral carotid arteries by the imaging core laboratory\n\nSubstudy 2 Inclusion:\n\n* All inclusion from Main Study\n* T2D at baseline per Main protocol criteria and be on a stable anti-hyperglycemic medication for at least 4 weeks prior to the baseline OGTT test\n* Willing to have the OGTT assessment started before 10 am\n\nMain Study Exclusion Criteria:\n\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential\n* Any of the following concomitant diseases\n* Planned coronary revascularization (PCI or CABG)\n* Major non-cardiac surgical or endoscopic procedure within past 6 months\n* Multi-vessel CABG surgery within the past 3 years\n* Symptomatic patients with Class IV heart failure (HF) (New York Heart Association \\[NYHA\\].\n* Uncontrolled hypertension\n* Uncontrolled diabetes\n* History or evidence of active tuberculosis (TB) infection Substudy 1 Exclusion\n* All Main exclusion\n* Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy\n* Patients with contraindications to MRI examination (brain aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator, prosthetic heart valves, cochlear implant, ocular foreign body or other implanted body, tattoos, implanted insulin pump, metal shrapnel or bullet)\n* Patients prone to claustrophobia or known anxiety disorders\n* BMI \\> 40 kg/m2 Substudy 2 Exclusion\n* This sub-study does not have any additional exclusion criteria.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components","description":"Time to occurrence of CEC (Cardiovascular clinical events adjudication committee) confirmed MACE, which was a composite endpoint consisting of CEC confirmed CV death, CEC confirmed non-fatal MI,or CEC confirmed non-fatal stroke. Patients with the CEC adjudicated reason for death of \"Unknown\" were counted as CV (cardiovascular) death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322","spread":null},{"groupId":"OG001","value":"320","spread":null},{"groupId":"OG002","value":"313","spread":null},{"groupId":"OG003","value":"535","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"137","spread":null},{"groupId":"OG003","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"159","spread":null},{"groupId":"OG002","value":"169","spread":null},{"groupId":"OG003","value":"292","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"158","spread":null},{"groupId":"OG002","value":"168","spread":null},{"groupId":"OG003","value":"291","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"91","spread":null}]}]}]},{"type":"PRIMARY","title":"Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid Artery","description":null,"classes":[]},{"type":"PRIMARY","title":"Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 Visits","description":null,"classes":[]},{"type":"SECONDARY","title":"Patients With Core Phase CEC Confirmed CV Death, Non-fatal MI, Non-fatal Stroke, or Hospitalization for Unstable Angina Requiring Unplanned Revascularization","description":"Occurrence of the composite cardiovascular endpoint consisting of cardiovascular death, non-fatal MI, non-fatal stroke or hospitalization for unstable angina requiring unplanned revascularization.\n\nMACE includes CV death, non-fatal MI and non-fatal stroke. CEC = Clinical Endpoints Committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":null},{"groupId":"OG001","value":"352","spread":null},{"groupId":"OG002","value":"344","spread":null},{"groupId":"OG003","value":"601","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Core Phase New Onset Type 2 Diabetes Among Patients With Pre-diabetes at Randomization","description":"Time to CEC confirmed new onset of type 2 diabetes among those with pre-diabetes at randomization (i.e. excluding those that are normoglycemic at baseline)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"161","spread":null},{"groupId":"OG003","value":"246","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Phase All-cause Mortality, Non-fatal MI, or Non-fatal Stroke","description":"Occurrence of the composite endpoint consisting of all-cause mortality, non-fatal IM, or non-fatal stroke","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"395","spread":null},{"groupId":"OG002","value":"394","spread":null},{"groupId":"OG003","value":"661","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Phase All-cause Mortality","description":"Number of participant deaths","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"238","spread":null},{"groupId":"OG002","value":"228","spread":null},{"groupId":"OG003","value":"375","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Adverse Events (Core Phase)","description":"Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the double-blind Core phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1987","spread":null},{"groupId":"OG001","value":"1970","spread":null},{"groupId":"OG002","value":"1872","spread":null},{"groupId":"OG003","value":"2915","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"355","spread":null},{"groupId":"OG001","value":"350","spread":null},{"groupId":"OG002","value":"267","spread":null},{"groupId":"OG003","value":"474","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"836","spread":null},{"groupId":"OG001","value":"812","spread":null},{"groupId":"OG002","value":"741","spread":null},{"groupId":"OG003","value":"1204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"117","spread":null},{"groupId":"OG003","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"270","spread":null},{"groupId":"OG002","value":"228","spread":null},{"groupId":"OG003","value":"399","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Adverse Events (Extension Phase)","description":"Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the Extension phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"788","spread":null},{"groupId":"OG001","value":"845","spread":null},{"groupId":"OG002","value":"793","spread":null},{"groupId":"OG003","value":"1250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"326","spread":null},{"groupId":"OG002","value":"322","spread":null},{"groupId":"OG003","value":"465","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"62","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Substudy 1 (Core Phase): Change From Baseline of the Total Vessel Wall Area at Month 3 in the Bifurcation Region of the Index Carotid Artery","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 1 (Core Phase): Mean Total Vessel Wall Area Across the Left and Right Carotid Artery at Month 3 and Month 24","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 1 (Core Phase): Change From Baseline in Corresponding Total Vessel Wall Area in the Left and Right Carotid Arteries","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 1 (Core Phase): The Existence of a Baseline Total Vessel Wall Area by Treatment Interaction as Well as the Consistency of the Treatment Effect Across Subgroups","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 2 (Core Phase): Change From Baseline in Insulin Sensitivity Index","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 2 (Core Phase): Change From Baseline in OGTT Stimulated Area Under Curve (AUC) 0-120 Min of Glucose Concentration, Insulin Concentration, Pro-insulin Concentration, and Insulin Concentration/Glucose Concentration Ratio","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 2 (Core Phase): Change From Baseline in Fasting Pro-Insulin Concentration/Insulin Concentration Ratio","description":null,"classes":[]},{"type":"SECONDARY","title":"Substudy 2 (Core Phase): Change From Baseline in OGTT Stimulated Area Under the Curve (AUC) 0-120 Min of C-peptide Concentration","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":759,"n":2263},"commonTop":["Viral upper respiratory tract infection","Hypertension","Back pain","Arthralgia","Upper respiratory tract infection"]}}}